Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

A phase I clinical trial of a new 5-valent rotavirus vaccine.

Luna EJ, Frazatti-Gallina NM, Timenetsky MC, Cardoso MR, Veras MA, Miraglia JL, Escobar AM, Grisi SJ, Raw I, Precioso AR.

Vaccine. 2013 Feb 4;31(7):1100-5. doi: 10.1016/j.vaccine.2012.12.020. Epub 2012 Dec 20.

2.

Immunogenicity of the pentavalent rotavirus vaccine among infants in two developing countries in Asia, Bangladesh and Vietnam.

Shin S, Anh DD, Zaman K, Yunus M, Mai le TP, Thiem VD, Azim T, Victor JC, Dallas MJ, Steele AD, Neuzil KM, Ciarlet M.

Vaccine. 2012 Apr 27;30 Suppl 1:A106-13. doi: 10.1016/j.vaccine.2011.11.091.

PMID:
22520119
3.

Immunogenicity of the pentavalent rotavirus vaccine in African infants.

Armah GE, Breiman RF, Tapia MD, Dallas MJ, Neuzil KM, Binka FN, Sow SO, Ojwando J, Ciarlet M, Steele AD.

Vaccine. 2012 Apr 27;30 Suppl 1:A86-93. doi: 10.1016/j.vaccine.2011.10.006.

PMID:
22520142
4.

A dose-escalation safety and immunogenicity study of a new live attenuated human rotavirus vaccine (Rotavin-M1) in Vietnamese children.

Dang DA, Nguyen VT, Vu DT, Nguyen TH, Nguyen DM, Yuhuan W, Baoming J, Nguyen DH, Le TL; Rotavin-M1 Vaccine Trial Group..

Vaccine. 2012 Apr 27;30 Suppl 1:A114-21. doi: 10.1016/j.vaccine.2011.07.118.

PMID:
22520120
5.

Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine.

Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM; Rotavirus Efficacy and Safety Trial (REST) Study Team..

N Engl J Med. 2006 Jan 5;354(1):23-33.

6.

Phase I trial of RV3-BB rotavirus vaccine: a human neonatal rotavirus vaccine.

Danchin M, Kirkwood CD, Lee KJ, Bishop RF, Watts E, Justice FA, Clifford V, Cowley D, Buttery JP, Bines JE.

Vaccine. 2013 May 28;31(23):2610-6. doi: 10.1016/j.vaccine.2013.04.008. Epub 2013 Apr 16.

PMID:
23597719
7.

Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants.

Salinas B, Pérez Schael I, Linhares AC, Ruiz Palacios GM, Guerrero ML, Yarzábal JP, Cervantes Y, Costa Clemens S, Damaso S, Hardt K, De Vos B.

Pediatr Infect Dis J. 2005 Sep;24(9):807-16.

PMID:
16148848
8.

Safety and immunogenicity of live attenuated quadrivalent human-bovine (UK) reassortant rotavirus vaccine administered with childhood vaccines to infants.

Clements-Mann ML, Dudas R, Hoshino Y, Nehring P, Sperber E, Wagner M, Stephens I, Karron R, Deforest A, Kapikian AZ.

Vaccine. 2001 Sep 14;19(32):4676-84.

PMID:
11535316
9.

Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States.

Rodriguez ZM, Goveia MG, Stek JE, Dallas MJ, Boslego JW, DiNubile MJ, Heaton PM.

Pediatr Infect Dis J. 2007 Mar;26(3):221-7.

PMID:
17484218
10.

Safety, efficacy, and immunogenicity of a live, quadrivalent human-bovine reassortant rotavirus vaccine in healthy infants.

Clark HF, Bernstein DI, Dennehy PH, Offit P, Pichichero M, Treanor J, Ward RL, Krah DL, Shaw A, Dallas MJ, Laura D, Eiden JJ, Ivanoff N, Kaplan KM, Heaton P.

J Pediatr. 2004 Feb;144(2):184-90. Erratum in: J Pediatr. 2004 Apr;144(4):558.

PMID:
14760258
11.

Efficacy of the oral pentavalent rotavirus vaccine in Mali.

Sow SO, Tapia M, Haidara FC, Ciarlet M, Diallo F, Kodio M, Doumbia M, Dembélé RD, Traoré O, Onwuchekwa UU, Lewis KD, Victor JC, Steele AD, Neuzil KM, Kotloff KL, Levine MM.

Vaccine. 2012 Apr 27;30 Suppl 1:A71-8. doi: 10.1016/j.vaccine.2011.11.094.

PMID:
22520140
12.

Methodology and lessons-learned from the efficacy clinical trial of the pentavalent rotavirus vaccine in Bangladesh.

Zaman K, Yunus M, El Arifeen S, Azim T, Faruque AS, Huq E, Hossain I, Luby SP, Victor JC, Dallas MJ, Lewis KD, Rivers SB, Steele AD, Neuzil KM, Ciarlet M, Sack DA.

Vaccine. 2012 Apr 27;30 Suppl 1:A94-100. doi: 10.1016/j.vaccine.2011.07.117.

PMID:
22520143
13.

Comparison of 2 different regimens for reactogenicity, safety, and immunogenicity of the live attenuated oral rotavirus vaccine RIX4414 coadministered with oral polio vaccine in South African infants.

Steele AD, Reynders J, Scholtz F, Bos P, de Beer MC, Tumbo J, Van der Merwe CF, Delem A, De Vos B.

J Infect Dis. 2010 Sep 1;202 Suppl:S93-100. doi: 10.1086/653550.

PMID:
20684724
14.

Safety and immunogenicity of pentavalent rotavirus vaccine in a randomized, double-blind, placebo-controlled study in healthy elderly subjects.

Lawrence J, He S, Martin J, Schödel F, Ciarlet M, Murray AV.

Hum Vaccin Immunother. 2014;10(8):2247-54. doi: 10.4161/hv.29107.

15.

Co-administration study in South African infants of a live-attenuated oral human rotavirus vaccine (RIX4414) and poliovirus vaccines.

Steele AD, De Vos B, Tumbo J, Reynders J, Scholtz F, Bos P, de Beer MC, Van der Merwe CF, Delem A.

Vaccine. 2010 Sep 7;28(39):6542-8. doi: 10.1016/j.vaccine.2008.08.034. Epub 2008 Sep 9.

PMID:
18786585
16.

Human and bovine rotavirus strain antigens for evaluation of immunogenicity in a randomized, double-blind, placebo-controlled trial of a single dose live attenuated tetravalent, bovine-human-reassortant, oral rotavirus vaccine in Indian adults.

Paul A, Babji S, Sowmyanarayanan TV, Dhingra MS, Ramani S, Kattula D, Kang G.

Vaccine. 2014 May 23;32(25):3094-100. doi: 10.1016/j.vaccine.2014.03.013. Epub 2014 Apr 2.

PMID:
24704505
17.

Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study.

Omenaca F, Sarlangue J, Szenborn L, Nogueira M, Suryakiran PV, Smolenov IV, Han HH; ROTA-054 Study Group..

Pediatr Infect Dis J. 2012 May;31(5):487-93. doi: 10.1097/INF.0b013e3182490a2c.

PMID:
22228231
18.

Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine.

Dennehy PH, Brady RC, Halperin SA, Ward RL, Alvey JC, Fischer FH Jr, Innis BL, Rathfon H, Schuind A, De Vos B; North American Human Rotavirus Vaccine Study Group..

Pediatr Infect Dis J. 2005 Jun;24(6):481-8.

PMID:
15933555
19.

Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.

Li RC, Li YP, Mo ZJ, Luo D, Huang T, Kong JL, Wang LH, Song NS, Liu A, Zhang H, Liao X, Karkada N, Han HH.

Hum Vaccin Immunother. 2013 Aug;9(8):1638-42. doi: 10.4161/hv.25076. Epub 2013 Jun 4.

20.

Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.

Laserson KF, Nyakundi D, Feikin DR, Nyambane G, Cook E, Oyieko J, Ojwando J, Rivers SB, Ciarlet M, Neuzil KM, Breiman RF.

Vaccine. 2012 Apr 27;30 Suppl 1:A61-70. doi: 10.1016/j.vaccine.2011.09.026.

PMID:
22520138

Supplemental Content

Support Center